• Stephen L Kates, John R Owen, Chao Xie, Youliang Ren, Gowrishankar Muthukrishnan, and Edward M Schwarz.
• Department of Orthopaedic Surgery, Virginia Commonwealth University, Richmond, VA, USA.
• Injury. 2024 Nov 1; 55 Suppl 6: 111631111631.

AbstractAlthough vaccines have been hailed as one of the greatest advances in medicine based on their unparalleled cost-effectiveness in eradicating life-threatening infectious diseases, their role in orthopedic trauma-related infections is unclear. This is largely because vaccines are primarily made against pathogens that cause communicable diseases rather than opportunistic infections secondary to trauma, and most successful vaccines are against viruses rather than biofilm forming bacteria. Nonetheless, the tremendous costs to patients and healthcare systems warrant orthopedic trauma vaccine research, which has been a focal topic in recent international consensus meetings on musculoskeletal infection. This subject was also covered at the 2023 Osteosynthesis and Trauma Care Foundation (OTCF) meeting in Rome, Italy, and the purpose of this supplement article is to (1) highlight the osteoimmunology, animal models, translational research and clinical pilots that were discussed, (2) the proposed future directions that could lead to diagnostics and prognostics that are critically needed for evidence-based decision making, and (3) vaccines and passive-immunization strategies that could potentially be utilized to treat patients with orthopedic infections.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

13 keywords...

hide…